The impact of antifungals on toll-like receptors

Frontiers in Microbiology

Volumn 5, Issue MAR, 2014, Pages

  Mihu, Mircea R ^a   Pattabhi, Rodney ^a   Nosanchuk, Joshua D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Amphotericin B; Antifungals; Caspofungin; Echinocandins; Toll like receptors; Voriconazole

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CD14 ANTIGEN; DECTIN 1; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TERBINAFINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ASPERGILLOSIS; CELL ACTIVATION; CYTOKINE RESPONSE; DRUG TOLERABILITY; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INNATE IMMUNITY; MYCOSIS; PROTEIN EXPRESSION; SHORT SURVEY; VAGINITIS;

EID: 84897930162     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2014.00099     Document Type: Short Survey

References (47)

1. Adjou, K. T., Deslys, J. P., Demaimay, R., and Dormont, D. (1997). Probing the dynamics of prion diseases with amphotericin B. Trends Microbiol. 5, 27-31. doi: 10.1016/S0966-842X(97)81771-4.
2. Aerts, A. M., Francois, I. E., Cammue, B. P., and Thevissen, K. (2008). The mode of antifungal action of plant, insect and human defensins. Cell Mol. Life Sci. 65, 2069-2079. doi: 10.1007/s00018-008-8035-0.
3. Arning, M., Kliche, K. O., Heer-Sonderhoff, A. H., and Wehmeier, A. (1995). Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38, 459-465. doi: 10.1111/j.1439-0507.1995.tb00020.x.
4. Bellocchio, S., Gaziano, R., Bozza, S., Rossi, G., Montagnoli, C., Perruccio, K., et al. (2005). Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J. Antimicrob. Chemother. 55, 214-222. doi: 10.1093/jac/dkh542.
5. Blanco, J. L., and Garcia, M. E. (2008). Immune response to fungal infections. Vet. Immunol. Immunopathol. 125, 47-70. doi: 10.1016/j.vetimm.2008.04.020.
6. Bochud, P. Y., Chien, J. W., Marr, K. A., Leisenring, W. M., Upton, A., Janer, M., et al. (2008). Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 359, 1766-1777. doi: 10.1056/NEJMoa0802629.
7. Brown, G. D. (2006). Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 6, 33-43. doi: 10.1038/nri1745.
8. Brown, G. D., Denning, D. W., and Levitz, S. M. (2012). Tackling human fungal infections. Science 336, 647. doi: 10.1126/science.1222236.
9. Cleary, J. D., Chapman, S. W., and Nolan, R. L. (1992). Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob. Agents Chemother. 36, 977-981. doi: 10.1128/AAC.36.5.977.
10. Dennehy, K. M., and Brown, G. D. (2007). The role of the beta-glucan receptor Dectin-1 in control of fungal infection. J. Leukoc. Biol. 82, 253-258. doi: 10.1189/jlb.1206753.
11. Denning, D. W. (2002). Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49, 889-891. doi: 10.1093/jac/dkf045.
12. Dutcher, J. D. (1968). The discovery and development of amphotericin B. Dis. Chest 54(Suppl. 1), 296-298. doi: 10.1378/chest.54.Supplement_1.296.
13. Ellis, D. (2002). Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49(Suppl. 1), 7-10. doi: 10.1093/jac/49.suppl_1.7.
14. Enoch, D. A., Ludlam, H. A., and Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options. J. Med. Microbiol. 55(Pt 7): 809-818. doi: 10.1099/jmm.0.46548-0.
15. Fanos, V., and Cataldi, L. (2000). Amphotericin B-induced nephrotoxicity: a review. J. Chemother. 12, 463-470. doi: 10.1179/joc.2000.12.6.463.
16. Fera, M. T., La Camera, E., and De Sarro, A. (2009). New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev. Anti Infect. Ther. 7, 981-998. doi: 10.1586/eri.09.67.
17. Ganz, T. (2003). Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3, 710-720. doi: 10.1038/nri1180.
18. Hagerty, J. A., Ortiz, J., Reich, D., and Manzarbeitia, C. (2003). Fungal infections in solid organ transplant patients. Surg. Infect. (Larchmt) 4, 263-271. doi: 10.1089/109629603322419607.
19. Hiemenz, J. W., and Walsh, T. J. (1996). Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2), S133-S144. doi: 10.1093/clinids/22.Supplement_2.S133.
20. Hube, B. (2009). Fungal adaptation to the host environment. Curr. Opin. Microbiol. 12, 347-349. doi: 10.1016/j.mib.2009.06.009.
21. Janeway, C. A. Jr., and Medzhitov, R. (2002). Innate immune recognition. Annu. Rev. Immunol. 20, 197-216. doi: 10.1146/annurev.immunol.20.083001.084359.
22. Kafetzis, D. A., Velissariou, I. M., Stabouli, S., Mavrikou, M., Delis, D., and Liapi, G. (2005). Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds? Int. J. Antimicrob. Agents 25, 26-30. doi: 10.1016/j.ijantimicag.2004.09.011.
23. Khoo, S. H., Bond, J., and Denning, D. W. (1994). Administering amphotericin B-a practical approach. J. Antimicrob. Chemother. 33, 203-213. doi: 10.1093/jac/33.2.203.
24. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., et al. (2003). Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54, 18-24. doi: 10.1016/S0195-6701(03)00085-9.
25. Lewis, R. E. (2011). Current concepts in antifungal pharmacology. Mayo Clin. Proc. 86, 805-817. doi: 10.4065/mcp.2011.0247.
26. Marr, K. A., Carter, R. A., Crippa, F., Wald, A., and Corey, L. (2002). Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34, 909-917. doi: 10.1086/339202.
27. Matsuo, K., Hotokezaka, H., Ohara, N., Fujimura, Y., Yoshimura, A., Okada, Y., et al. (2006). Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol. Immunol. 50, 337-347. doi: 10.1111/j.1348-0421.2006.tb03792.x.
28. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A. Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397. doi: 10.1038/41131.
29. Moretti, S., Bozza, S., D'Angelo, C., Casagrande, A., Della Fazia, M. A., Pitzurra, L., et al. (2012). Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis. Antimicrob. Agents Chemother. 56, 4268-4276. doi: 10.1128/AAC.05198-11.
30. Moretti, S., Bozza, S., Massi-Benedetti, C., Prezioso, L., Rossetti, E., Romani, L., et al. (2013). An immunomodulatory activity of micafungin in preclinical aspergillosis. J. Antimicrob. Chemother. doi: 10.1093/jac/dkt457 [Epub ahead of print].
31. Morris, M. I., and Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1. Am. J. Health Syst. Pharm. 63, 1693-1703. doi: 10.2146/ajhp050464.p1.
32. Newton, K., and Dixit, V. M. (2012). Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4, pii: a006049. doi: 10.1101/cshperspect.a006049.
33. Perlin, D. S. (2011). Current perspectives on echinocandin class drugs. Future Microbiol. 6, 441-457. doi: 10.2217/fmb.11.19.
34. Pfaller, M. A. (2012). Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1 Suppl.), S3-S13. doi: 10.1016/j.amjmed.2011.11.001.
35. Pfaller, M. A., and Diekema, D. J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163. doi: 10.1128/CMR.00029-06.
36. Plantinga, T. S., Johnson, M. D., Scott, W. K., van de Vosse, E., Velez Edwards, D. R., Smith, P. B., et al. (2012). Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205, 934-943. doi: 10.1093/infdis/jir867.
37. Razonable, R. R., Henault, M., Lee, L. N., Laethem, C., Johnston, P. A., Watson, H. L., et al. (2005). Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antimicrob. Agents Chemother. 49, 1617-1621. doi: 10.1128/AAC.49.4.1617-1621.2005.
38. Roeder, A., Kirschning, C. J., Rupec, R. A., Schaller, M., Weindl, G., and Korting, H. C. (2004). Toll-like receptors as key mediators in innate antifungal immunity. Med. Mycol. 42, 485-498. doi: 10.1080/13693780400011112.
39. Romani, L. (2004). Immunity to fungal infections. Nat. Rev. Immunol. 4, 1-23. doi: 10.1038/nri1255.
40. Salvenmoser, S., Seidler, M. J., Dalpke, A., and Muller, F. M. (2010). Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs. FEMS Immunol. Med. Microbiol. 60, 74-77. doi: 10.1111/j.1574-695X.2010.00720.x.
41. Sau, K., Mambula, S. S., Latz, E., Henneke, P., Golenbock, D. T., and Levitz, S. M. (2003). The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568. doi: 10.1074/jbc.M306137200.
42. Shoham, S., and Marr, K. A. (2012). Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 7, 639-655. doi: 10.2217/fmb.12.28.
43. Simitsopoulou, M., Roilides, E., Paliogianni, F., Likartsis, C., Ioannidis, J., Kanellou, K., et al. (2008). Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52, 3301-3306. doi: 10.1128/AAC.01018-07.
44. Steinstraesser, L., Koehler, T., Jacobsen, F., Daigeler, A., Goertz, O., Langer, S., et al. (2008). Host defense peptides in wound healing. Mol. Med. 14, 528-537. doi: 10.2119/2008-00002.Steinstraesser.
45. Wenzel, R. P., and Edmond, M. B. (2001). The impact of hospital-acquired bloodstream infections. Emerg. Infect. Dis. 7, 174-177. doi: 10.3201/eid0702.010203.
46. Wheeler, R. T., Kombe, D., Agarwala, S. D., and Fink, G. R. (2008). Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog. 4:e1000227. doi: 10.1371/journal.ppat.1000227.
47. Zonios, D. I., and Bennett, J. E. (2008). Update on azole antifungals. Semin. Respir. Crit. Care Med. 29, 198-210. doi: 10.1055/s-2008-1063858.